Drug Trial Radar · NCT07261150
Histoplasmosis Induction and Consolidation Therapy Factorial Randomized Clinical Trial (Histo-FACT)
Last checked: Nov 19, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
664
Planned (sponsor's estimate)
Start
Dec 1, 2026
Primary completion
Dec 31, 2030
Study completion Dec 31, 2030
Sponsor
- Lead sponsor
- University of MinnesotaAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Federal University of Health Science of Porto Alegre
- First posted
- Dec 3, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of the study is threefold: 1. Assess the safety and efficacy of a single high-dose intravenous (LAmB 10mg/kg) compared to the SOC daily dosing (3mg/kg) of the same medication for induction therapy in moderate to severe histoplasmosis. 2. Assess the safety and efficacy of oral posaconazole 300mg delayed-release tablets three times daily for two days then once daily for consolidation therapy compared to SOC oral itraconazole 200 mg capsules three times daily for three days then twice daily in moderate to severe histoplasmosis 3. Assess the safety and efficacy of 6 months of consolidation therapy compared to the SOC 12 months of consolidation therapy in persons with HIV on appropriate antiretroviral therapy.
Conditions
- Histoplasmosis
Interventions
LAmB BDrug
intravenous liposomal amphotericin B (10mg/kg)
PosaconazoleDrug
Posaconazole delayed-release tabs, 300mg twice daily on day 1 then once daily
World Health Organization (WHO)-recommended SOCDrug
daily intravenous liposomal amphotericin B 3mg/kg, for 2 weeks or at least 7 days if felt stable for discharge per the clinician
WHO-recommended SOC ItraconazoleDrug
200mg capsules three times daily x 3 days then twice daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- Mortality at 2 weeksTime frame: Week 2
- Mortality at 26 weeksTime frame: Week 26
- SAE-free survival between 26 and 52 weeks from induction therapy among those who survived 26 weeksTime frame: Week 52
Locations
2 sites in 2 countries. Site status is shown where the registry gives one.
University of Minnesota
Minneapolis, Minnesota
Universidade Federal de Ciências da Saúde de Porto Alegre
Porto Alegre, Brazil
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.